Even if the risk of developing breast cancer is low or moderate for most patients, screening might be advisable if BAP1-deficient breast cancers are confirmed to be associated with poor prognosis and/or warrant specific therapeutic approaches. The gene discussed is BAP1; the disease is breast cancer.